Compare OIS & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OIS | PEPG |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.3M | 353.9M |
| IPO Year | 2000 | 2022 |
| Metric | OIS | PEPG |
|---|---|---|
| Price | $12.64 | $4.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $14.00 | $11.67 |
| AVG Volume (30 Days) | ★ 1.2M | 660.7K |
| Earning Date | 04-30-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,088,133,000.00 | N/A |
| Revenue This Year | $3.73 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 62.26 | N/A |
| 52 Week Low | $3.08 | $0.89 |
| 52 Week High | $14.50 | $7.80 |
| Indicator | OIS | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 60.93 | 37.78 |
| Support Level | $11.52 | $4.36 |
| Resistance Level | $14.50 | $5.50 |
| Average True Range (ATR) | 0.51 | 0.51 |
| MACD | -0.16 | -0.17 |
| Stochastic Oscillator | 73.81 | 10.53 |
Oil States International Inc is a provider of manufactured products and services to the energy, industrial and military sectors. Manufactured products include engineered capital equipment as well as products consumed in the drilling, well construction and production of oil and natural gas. The company sells its products and services to national oil and natural gas companies, oil and natural gas companies, onshore and offshore drilling companies and other oilfield services, defense and industrial companies. The company operates through three business segments, Offshore Manufactured Products, Completion and Production Services and Downhole Technologies. It gains maximum revenue from Offshore Manufactured Products.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.